Neuro-oncology最新文献

{"title":"Erratum to: High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.","authors":"","doi":"10.1093/neuonc/noaf150","DOIUrl":"https://doi.org/10.1093/neuonc/noaf150","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvements in survival for glioblastoma in the post-Stupp protocol era.","authors":"Mackenzie Price, Justin T Low, Gordon Chavez, Patrick Conlon, Nick Avgeropoulos, Carol Kruchko, Gino Cioffi, Kristin A Waite, Jill S Barnholtz-Sloan, Quinn T Ostrom","doi":"10.1093/neuonc/noaf134","DOIUrl":"https://doi.org/10.1093/neuonc/noaf134","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selumetinib for Adults with NF1-Associated Plexiform Neurofibromas: Insights from the KOMET Study.","authors":"Sani Gandhi, Phioanh Leia Nghiemphu","doi":"10.1093/neuonc/noaf174","DOIUrl":"https://doi.org/10.1093/neuonc/noaf174","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Characterizing long-term neurocognitive outcomes through diffusion tensor imaging in childhood brain tumor survivors.","authors":"","doi":"10.1093/neuonc/noaf161","DOIUrl":"https://doi.org/10.1093/neuonc/noaf161","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Point/counterpoint: The role of re-resection in recurrent glioblastoma.","authors":"Jacob S Young, Mitchel S Berger, Arian Lasocki, Abigail K Suwala, Maximilian Niyazi, Susan M Chang, Oliver Schnell, Philipp Karschnia","doi":"10.1093/neuonc/noaf127","DOIUrl":"https://doi.org/10.1093/neuonc/noaf127","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspective.","authors":"Martin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, Joshua E Allen, Samuel C Blackman, Mark W Kieran, Joerg C Tonn, Philipp Karschnia, Maarten Wijnenga, Johan Pallud, Robert J Young, Raymond Y Huang, Ingo K Mellinghoff, John de Groot, Anouk van der Hoorn, Gilbert Youssef, Shawn L Hervey-Jumper, Michael A Vogelbaum, Susan M Chang, Patrick Y Wen","doi":"10.1093/neuonc/noaf173","DOIUrl":"https://doi.org/10.1093/neuonc/noaf173","url":null,"abstract":"<p><p>The RANO criteria for response to treatment in glioma make a distinction between enhancing and unenhancing tumors, which reflects assessment of a different biological process underlying the MRI findings in enhancing and non-enhancing tumors. The recent regulatory approval of tovorafenib has also considered the patients with minor responses (25% - 50% decrease) based on the 2D measurement on T2/FLAIR MR imaging, while incorporating other measures of patient benefit. The INDIGO placebo controlled trial led to the regulatory approval of vorasidenib based on the increase in PFS in the active treatment arm, as measured by blinded independent radiology review using the 2D RANO criteria. With that, more insight in the regulatory requirements for approval in low grade tumors has been obtained, but other issues in assessing outcome in studies on low grade enhancing tumors remain. These include the added value of volumetric assessment instead of 2D assessments, and assessment of tumor growth rate as an early marker of outcome. This manuscript gives an overview of the current perspective on and challenges of assessing outcome in trials on unenhancing glioma, with both regulatory and clinical perspectives.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype: a grade 1 oligodendroglioma of young patients?","authors":"Filippo Nozzoli, Ramin Rahmanzade, Simone Schmid, Leonille Schweizer, Daniel Schrimpf, Dennis Friedel, Kirsten Göbel, David E Reuss, Rouzbeh Banan, Philipp Sievers, Stefan Pusch, Henri Bogumil, Felix Hinz, Abigail K Suwala, Fuat Kaan Aras, Lukas Friedrich, Simona Osella-Abate, Alessia Andrea Ricci, Alessandra Macciotta, Thorsten Simon, Gudrun Fleischhack, Kathy Keyvani, Jordan R Hansford, Dong-Anh Khuong-Quang, Philippe Schucht, Theoni Maragkou, Tareq A Juratli, Matthias Meinhardt, Sabrina Zechel, Christine Stadelmann, Roland Coras, Oliver W Sakowitz, Benjamin Goeppert, Jens Schittenhelm, Nima Etminan, Miriam Ratliff, Christel Herold-Mende, Stefan M Pfister, Wolfgang Wick, Sandro M Krieg, Andreas von Deimling, Felix Sahm, Luca Bertero","doi":"10.1093/neuonc/noaf141","DOIUrl":"https://doi.org/10.1093/neuonc/noaf141","url":null,"abstract":"<p><strong>Background: </strong>Oligodendrogliomas, characterized by isocitrate dehydrogenase (IDH) mutations and 1p/19q codeletion, often exhibit telomerase reverse transcriptase promoter (TERTp) mutations which have been linked to telomere maintenance (TM) and tumour proliferation. Although there are a few reports on a TERTp-wildtype subset of these tumours in adolescents and young adults, the frequency, molecular characteristics and prognostic implications of TERTp-wildtype status in oligodendrogliomas remains elusive.</p><p><strong>Methods: </strong>We retrospectively analysed 166 IDH-mutant and 1p/19q-codeleted oligodendroglioma cases through comprehensive histopathological review and molecular analyses, including Sanger sequencing, DNA methylation profiling and whole exome sequencing (WES).</p><p><strong>Results: </strong>A TERTp-wildtype status was observed in 20/166 cases (12.0%) and was significantly associated with noticeably young age (p<0.001), CNS WHO grade 2 (p=0.003), and the absence of additional DNA copy number variations (CNVs) beyond the pathognomonic 1p/19q codeletion (p<0.001). Epigenetic profiling demonstrated TERTp-wildtype tumours shaped a distinct subgroup at the utmost periphery of TERTp-mutant oligodendrogliomas. Methylation analysis of the upstream and proximal TERTp regions revealed that, in line with the absence of genetic alterations, epigenetic regulation does not favour TERT overexpression in TERTp-wildtype oligodendrogliomas. WES showed no TM-related genes alterations in TERTp-wildtype cases. Cox regression analysis confirmed TERTp-wildtype status as an independent prognostic factor for more favourable progression-free survival (PFS) (p=0.009).</p><p><strong>Conclusions: </strong>In conclusion, \"oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype\" represents a distinct molecular subgroup associated with younger age and a better clinical course compared to CNS WHO grade 2 oligodendrogliomas.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRD2 Bromodomain-Mediated Regulation of Cell State Plasticity Modulates Therapy Response in Glioblastoma.","authors":"Raghavendra Vadla, Brett Taylor, Yohei Miyake, Benjamin Lin, Daisuke Kawauchi, Shunichiro Miki, Nidhi Nathwani, Brandon M Jones, Yashpreet Kaur, Abhinaba Banerjee, Philip Pham, Jonathan Tsang, Albert Baldwin, David A Nathanson, Donald P Pizzo, C Ryan Miller, Frank B Furnari","doi":"10.1093/neuonc/noaf169","DOIUrl":"https://doi.org/10.1093/neuonc/noaf169","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM) displays remarkable cell state plasticity, a major contributor to therapeutic resistance and tumor progression. While epigenetic mechanisms play a central role in driving this plasticity, the key regulators remain poorly understood, and developing effective therapeutic strategies targeting them has been challenging.</p><p><strong>Methods: </strong>We investigated the role of BRD2, a key regulator of NF-κB mediated mesenchymal (MES) transition, using GBM patient-derived xenograft (PDX) cell lines, CRISPR-mediated knock-in/knockout approaches, RNA-seq, and in vitro and in vivo modeling. BET inhibitors were employed to target MES gene expression and sensitize GBM to radiation therapy.</p><p><strong>Results: </strong>We found that PTEN loss induces RelA chromatin localization and acetylation-mediated recruitment of BRD2 to the MES gene promoters. BRD2 binding is essential for maintaining MES gene expression and phenotype. Genetic ablation or loss-of-function mutation of BRD2 bromodomains reverses MES transition, enhances radiation sensitivity, and improves survival in orthotopic xenograft models. Additionally, treatment with a brain-penetrant BD2-selective inhibitor suppresses the MES phenotype and increases radiation sensitivity of GBM stem cells in vitro.</p><p><strong>Conclusion: </strong>Our study identifies BRD2 as a key mediator of MES transition in GBM, with its bromodomains playing a crucial role in driving cell state plasticity. Targeting BRD2 with BD2-selective inhibitors offers a promising therapeutic strategy to overcome radiation resistance and improve outcomes for GBM patients.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation.","authors":"Florien W Boele, Sé M Frances, Amélie Darlix, Francois Ducray, Stéphanie Cartalat, Estelle Guerdoux, Emeline Tabouret, Michael C Burger, Isabelle Rydén, Annika Malmstrom, Elodie Vauleon, Tomas Kazda, Mirjam Renovanz, Jan-Michael Werner, Liam Welsh, Paul Sanghera, Caroline Dehais, Isacco Desideri, Catherine McBain, Shaveta Mehta, Hannah Lord, Rajesh Jena, Karen Foweraker, Keyoumars Ashkan, Julien Engelhardt, Veronique Bourg, Ulrich Herrlinger, Aaron Lawson McLean, Caroline Hertler, Lene Haldbo-Classen, Rikke H Dahlrot, Georges Noel, Xavier Durando, Ioana Hrab, Evangelia Razis, Michael Weller, Aida Muhic, Martin Klein","doi":"10.1093/neuonc/noaf172","DOIUrl":"https://doi.org/10.1093/neuonc/noaf172","url":null,"abstract":"<p><strong>Background: </strong>Patients with oligodendroglioma have a relatively favourable prognosis. The long-term impacts of the tumour itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.</p><p><strong>Methods: </strong>In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumour location; treatments delivered; time since treatment; current medication;) were explored with regression analyses.</p><p><strong>Results: </strong>In total, 237 patients M=9.9 years post-diagnosis (sd=4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (post-hoc analyses for cumulative radiotherapy dose: not significant).</p><p><strong>Conclusions: </strong>In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning.</p><p><strong>Trial registration: </strong>NCT04708548.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interferon-γ Drives Anti-Tumor Immunity in Leptomeningeal Metastasis: A Potential Therapeutic Strategy.","authors":"Andrew F Kurlich, Grayson Whitt, Kelly M Hotchkiss, Mustafa Khasraw","doi":"10.1093/neuonc/noaf166","DOIUrl":"https://doi.org/10.1093/neuonc/noaf166","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}